Basic Information
RELVAR ELLIPTA INHALATION POWDER 200MCG/25MCG
POWDER, METERED
Regulatory Information
SIN14737P
February 24, 2015
Prescription Only
Therapeutic
RESPIRATORY (INHALATION)
August 10, 2023
June 3, 2025
XR03AK10
Company Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Active Ingredients
Strength: 200 mcg/dose
Strength: 25 mcg/dose
Detailed Information
Contraindications
**Contraindications** _RELVAR ELLIPTA_ is contraindicated in patients with severe milk-protein allergy or who have demonstrated hypersensitivity to either _RELVAR ELLIPTA_ or any of the excipients.
Indication Information
**Indications** **ASTHMA** _RELVAR ELLIPTA_ is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: - patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting beta2-agonists - patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist **COPD** RELVAR ELLIPTA is indicated for the symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.